TORNTPHARM · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 47/100 — Quality 64 · Valuation 0 · Growth 41 · Momentum 95
| Share price | ₹5,005.40 |
| Market cap | ₹1.47 lakh Cr |
| P/E ratio | 64.5 |
| P/B ratio | 17.4 |
| ROCE | 28.5% |
| Dividend yield | 0.81% |
| Book value | ₹249.47 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹13,980 Cr | ₹2,138 Cr | 33.0% |
| 2025 | ₹11,516 Cr | ₹1,911 Cr | 32.0% |
| 2024 | ₹10,728 Cr | ₹1,656 Cr | 31.0% |
| 2023 | ₹9,620 Cr | ₹1,245 Cr | 30.0% |
| 2022 | ₹8,508 Cr | ₹777 Cr | 29.0% |
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, cosmo-dermatology, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The co